We are exploring the genetic and epigenetic mechanisms underlying lethal cancers of the genitourinary tract with the goal of translating discovery in to novel therapies. Our approach couples translational research to clinical investigation in GU malignancies at Cleveland Clinic's Lerner Research Institute. We are developing powerful tools for identifying predictive and prognostic biomarkers as well as for therapeutic target discovery. The mission of our lab is to reduce the burden of prostate and bladder cancer through fundamental discovery and to improve the lives of cancer patients.
We are grateful for support from: